Ruben Mesa
Developments in Myelofibrosis: Ongoing Trials and the Significance of Mutations
Mayo Clinic expert, Dr. Ruben Mesa provides an update from the 2012 American Society of Hematology Meeting on important news for patients living with Myelofibrosis. He talks about where we are in understanding myeloproliferative disorders and what genetic changes patients experience that could potentially predict the behavior of the disease.… Continue reading
Myelofibrosis and Bone Marrow Transplant – Mayo Clinic
Ruben Mesa, MD and Veena Fauble, MD, Mayo Clinic hematologists, discuss bone marrow transplant as a treatment option for patients diagnosed with myelofibrosis.
A quote for you...
Powered By Optimism Quotes
Study Results: Ruxolitinib and Myelofibrosis – Mayo Clinic
Dr. Ruben Mesa, MD, hematologist at Mayo Clinic in Arizona, discusses study findings which show that Ruxolitinib helps reduce symptoms of myelofibrosis.
A quote for you...
Powered By Optimism Quotes
Myelofibrosis 2012 Update – Mayo Clinic
Ruben Mesa, MD, hematologist at Mayo Clinic in Arizona, discusses the updates in the treatment and management of myelofibrosis.
Related Blogs
A quote for you...
Powered By Optimism Quotes
Study Finds Ruxolitinib Effective in Reducing Myelofibrosis Symptoms – Mayo Clinic
Ruben Mesa, MD, hematologist at Mayo Clinic in Arizona, discusses findings from a study published in the New England Journal of Medicine which found Ruxolitinib effectively improves the quality of life and reduces symptoms for those with intermediate and advanced forms of myelofibrosis.
Related Blogs
A quote for you...
Powered By Optimism Quotes
Ruxolinitib Better at Reducing Myelofibrosis Symptoms
Ruben Mesa, MD of Mayo Clinic Arizona discusses a new more effective treatment for symptoms of myelofibrosis.
Related Blogs
A quote for you...
Powered By Optimism Quotes
Myelofibrosis Research Update – Mayo Clinic
Ruben Mesa, MD, Chair of Hematology and Medical Oncology at Mayo Clinic in Arizona, discusses the findings of the COMFORT-I, randomized, double-blind, phase III trial of JAK1/2 inhibitor Ruxolitinib vs. placebo in intermediate and high risk myelofibrosis.
Related Blogs
A quote for you...
Powered By Optimism Quotes